FDA Approves Merck’s WELIREG® (belzutifan) for Advanced Renal Cell Carcinoma

 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

https://www.marketscreener.com/quote/stock/MERCK-CO-INC-13611/news/FDA-Approves-Merck-s-WELIREG-belzutifan-for-the-Treatment-of-Patients-With-Advanced-Renal-Cell-45574413/